BioMarin Pharmaceutical (BMRN) Projected to Post Quarterly Earnings on Wednesday

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) will likely be issuing its quarterly earnings data after the market closes on Wednesday, February 19th. Analysts expect the company to announce earnings of $0.54 per share and revenue of $711.05 million for the quarter. Persons interested in participating in the company's earnings conference call can do so using this link.

BioMarin Pharmaceutical Trading Up 0.7 %

BMRN traded up $0.43 during trading on Friday, hitting $64.85. The company's stock had a trading volume of 1,048,855 shares, compared to its average volume of 1,674,690. The firm's 50 day moving average price is $64.86 and its 200-day moving average price is $71.56. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.27 and a quick ratio of 2.62. The stock has a market cap of $12.36 billion, a PE ratio of 38.83, a PEG ratio of 0.57 and a beta of 0.28. BioMarin Pharmaceutical has a twelve month low of $60.63 and a twelve month high of $94.85.

Analysts Set New Price Targets

Several analysts recently issued reports on BMRN shares. Citigroup lowered their price target on BioMarin Pharmaceutical from $93.00 to $81.00 and set a "neutral" rating for the company in a report on Wednesday, October 30th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $90.00 price target on shares of BioMarin Pharmaceutical in a research report on Thursday, December 12th. Wolfe Research started coverage on shares of BioMarin Pharmaceutical in a research note on Friday, November 15th. They set an "outperform" rating and a $95.00 price objective on the stock. Robert W. Baird dropped their price target on shares of BioMarin Pharmaceutical from $72.00 to $65.00 and set a "neutral" rating on the stock in a research note on Wednesday, October 30th. Finally, Canaccord Genuity Group dropped their price target on shares of BioMarin Pharmaceutical from $93.00 to $84.00 and set a "hold" rating on the stock in a research note on Wednesday, October 30th. Seven investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $94.20.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.